Moderna (MRNA) –
-
Form 4 Moderna, Inc. For: Apr 17 Filed by: AFEYAN NOUBAR
-
Form 144 Moderna, Inc. Filed by: AFEYAN NOUBAR
-
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
-
Form 4 Moderna, Inc. For: Apr 15 Filed by: Hoge Stephen
-
Form 144 Moderna, Inc. Filed by: Hoge Stephen
-
Form 4 Moderna, Inc. For: Apr 10 Filed by: AFEYAN NOUBAR
-
Form 144 Moderna, Inc. Filed by: AFEYAN NOUBAR
-
Form SC 13G/A Moderna, Inc. Filed by: VANGUARD GROUP INC
-
Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
-
Form 4 Moderna, Inc. For: Apr 05 Filed by: Mock James M
-
Moderna jumps as vaccine shows benefit in head and neck cancer in early study
-
Midday movers: Coinbase falls; Pfizer and Moderna rise
-
2 reasons why Moderna stock is surging today
-
Jefferies Reiterates Buy Rating on Moderna (MRNA): 'New Cancer Vaccine Data at AACR in Head/Neck'
-
Moderna (MRNA) call put ratio 1.1 calls to 1 put as share price up 8.3%
-
Moderna (MRNA) Climbs 9.4%
-
Form 144 Moderna, Inc. Filed by: Mock James M
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
Form 4 Moderna, Inc. For: Apr 03 Filed by: AFEYAN NOUBAR
-
Arbutus Biopharma (ABUS) Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (MRNA)
-
Form 144 Moderna, Inc. Filed by: AFEYAN NOUBAR
-
Moderna shares fall after judge sides with Arbutus in patent fight
-
Arbutus Biopharma (ABUS) Gains, Moderna (MRNA) Declines Following Order in Patent Case
-
Moderna (MRNA) Announces Publication of Phase 1/2 Interim Data on mRNA-3927
-
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
-
Form 4 Moderna, Inc. For: Mar 27 Filed by: AFEYAN NOUBAR
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Raised to $125 at Jefferies
-
Moderna (MRNA) PT Raised to $125 at Jefferies ahead of RSV launch and CMV data
-
Goldman Sachs Reiterates Buy Rating on Moderna (MRNA) after Vaccines Day
-
Form 144 Moderna, Inc. Filed by: AFEYAN NOUBAR
-
Midday movers: GameStop falls; Merck, Robinhood and Moderna rise
-
Moderna (MRNA) call put ratio 1.7 calls to 1 put amid investor meeting
-
CARsgen Announced 2023 Annual Results
-
Moderna secures $750 million from Blackstone Life Sciences to develop flu shots
-
Blackstone (BX) to Provide Up to $750M for Moderna's (MRNA) Influenza Program
-
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
-
Moderna (MRNA) Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
-
Moderna (MRNA) option implied volatility into investor event
-
UBS Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
-
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
-
Form 4 Moderna, Inc. For: Mar 20 Filed by: AFEYAN NOUBAR
-
Form DEFA14A Moderna, Inc.
-
Form DEF 14A Moderna, Inc. For: May 06
-
Form 144 Moderna, Inc. Filed by: AFEYAN NOUBAR
-
Moderna (MRNA) Trades Lower in Sympathy with BioNTech (BNTX)
-
Form 4 Moderna, Inc. For: Mar 15 Filed by: Hoge Stephen
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Back to MRNA Stock Lookup